Skip to main
EXEL

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 28%
Hold 39%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis Inc. continues to exhibit strong growth potential driven by its leading product, cabozantinib, which has established itself as a key treatment in renal cell carcinoma (RCC) and has expanded into neuroendocrine tumors (NETs) following recent label approvals based on promising study outcomes. The positive momentum surrounding zanzalintinib, particularly its favorable overall survival data in the metastatic colorectal cancer population, further underscores Exelixis's capacity for innovation and market expansion. Ongoing clinical trial successes and the potential for new indications signal a sustainable growth trajectory, reinforcing confidence in Exelixis's long-term financial prospects.

Bears say

Exelixis Inc. faces a significant revenue decline projected at 80% by 2032 due to the impending patent cliff in 2031, which is substantially greater than the Street's estimate of 68%. The company encounters multiple competitive risks, including potential market share erosion for its key product, cabozantinib (Cabo), and uncertainty regarding the successful launch in new indications such as HCC. Additionally, developmental risks concerning zanzalintinib and the likelihood of delays or failures in regulatory approvals further contribute to a cautious outlook on the company’s financial stability.

Exelixis (EXEL) has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 28% recommend Buy, 39% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 18 analysts, Exelixis (EXEL) has a Buy consensus rating as of Jan 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.